This may be simply attributed to the expression levels of RocA targets (eIF4A1, eIF4A2 and DDX3X), which are much higher in hematological cancer tissues than in normal tissues (data not shown). The gene discussed is EIF4A1; the disease is hematopoietic and lymphoid cell neoplasm.